PortalPublikationenBosutinib versus imatinib in newly diagnosed chronic-phase c...

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

Links

  • Jorge E Cortes
  • Dong-Wook Kim
  • Hagop M Kantarjian
  • Tim Brümmendorf
  • Irina Dyagil
  • Laimonas Griskevicius
  • Hemant Malhotra
  • Christine Powell
  • Karïn Gogat
  • Athena M Countouriotis
  • Carlo Gambacorti-Passerini

Beteiligte Einrichtungen

Abstract

Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid leukemia (CML).

Bibliografische Daten

OriginalspracheEnglisch
Aufsatznummer28
ISSN0732-183X
StatusVeröffentlicht - 2012
pubmed 22949154